Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1

Status

Active not recruiting 4Completed 2Terminated 1No longer available 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4Tumor-Agnostic 1Lymphoid 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Primary Myelofibrosis 4Neoplasms 3Myeloproliferative Disorders 2Thrombocythemia, Essential 1Polycythemia Vera 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine 23Cyclophosphamide 23fludarabine phosphate 18Tacrolimus 16ruxolitinib 15Melphalan 15Azacitidine 14venetoclax 13Whole-Body Irradiation 12Mycophenolic Acid 12Cytarabine 11Busulfan 11Thiotepa 9Specimen Handling 9Stem Cell Transplantation 8Granulocyte Colony-Stimulating Factor 8Decitabine 8Biopsy 8Peripheral Blood Stem Cell Transplantation 7Imatinib Mesylate 7decitabine and cedazuridine drug combination 6Sirolimus 6Methotrexate 6thymoglobulin 5nilotinib 5X-Rays 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Magnetic Resonance Spectroscopy 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × navitoclax × Myeloid × Clear all
NCT05455294 2026-01-28

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
16 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT04468984 2026-01-09

TRANSFORM-2

AbbVie

Phase 3 Active not recruiting
330 enrolled
Myeloid

Neoplasms, Primary Myelofibrosis

NCT04454658 2025-07-16

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

AbbVie

Phase 1 Active not recruiting
21 enrolled
Myeloid

Neoplasms, Primary Myelofibrosis

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

AbbVie

Phase 1 Active not recruiting
85 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡